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Introduction
Infection with HIV is a global health problem, with over
2 million AIDS-related deaths per year (http://www.una-
ids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/
2009/default.asp). Currently the only effective treatment
for the disease is Highly Active Anti-Retroviral Therapy
(HAART). Although HAART controls the disease, com-
plete eradication of the virus has yet to be achieved.
Addressing this significant global health problem calls for
the development of preventative and therapeutic vaccines.
A greater understanding of the immune response to HIV
and the mechanisms of viral immune evasion will facili-
tate this goal as well as further the development of thera-
peutics to eliminate HIV infection.
Major histocompatibility complex class I molecules
(MHC-I) are necessary for an effective host immune
response to HIV infection. MHC-I present viral peptides
to CD8+ T cells and serve as ligands for killer cell immu-
noglobulin-like receptors (KIRs). A subset of MHC-I allo-
types are associated with delayed disease progression and
effective control of viral replication, most notably HLA-
B*5701. Recently, genome-wide association studies have
implicated a role for high HLA-C surface expression in
the control of HIV.1–3 This review will summarize these
findings, supporting a role for HLA-C in HIV disease
progression. Insight gained from these studies will shed
light on the role of these complex molecules in the innate
and adaptive immune responses.
HLA-C
The MHC-I locus on chromosome 6 in the human gen-
ome comprises two groups, the highly polymorphic classi-
cal class I molecules (HLA-A, -B and -C)and the
conserved non-classical molecules (HLA-E, -F and –G)
(reviewed in ref. 4). There is evidence that evolution of
the HLA-A, -B and -C loci is driven by pathogen-medi-
ated selection. The HLA-A and -B molecules in particular
are highly polymorphic with the greatest variability found
within the peptide-binding region, which supports their
function in presentation of diverse antigens to cytotoxic
T lymphocytes (CTLs).5 HLA-C is the most recently
evolved of the classical MHC-I alleles and is restricted to
humans and great apes;4,6 and fewer alleles of HLA-C
have been identified. There are also functional differences
among these molecules that may restrict diversity; KIRs
recognize all HLA-C allotypes, but only some HLA-A and
-B allotypes.7 HLA-C biology is still under active investi-
gation to define its role in the immune response and the
selective pressures that define its diversity (for recent
review see ref. 8).
The HLA-C protein is a heterodimer composed of a
membrane-bound mature heavy chain and a light chain,
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Summary
Recently, genome-wide association studies have identified the major histo-
compatibility complex class I protein HLA-C as an important molecule
that affects HIV disease progression. The association between HLA-C and
HIV disease outcome was originally determined through a single nucleo-
tide polymorphism (SNP) 35 kb upstream of the HLA-C locus. More
recent work has focused on elucidating the functional significance of the -
35 SNP, and several groups now have demonstrated HLA-C surface
expression to be a key element in control of HIV viral load, with higher
surface expression associating with slower disease progression. Most
recently, control of HLA-C surface expression has been correlated with
the presence of microRNA binding sites that affect HLA-C expression and
control of HIV disease. This review highlights these results and explores
the ways in which HLA-C surface expression could affect immune system
function in the setting of HIV disease.
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b2-microglobulin (b2M). HLA-C plays a dual role in that
it can present antigens to CTLs and it can inhibit natural
killer (NK) cell (and possibly also CTL) lysis via its inter-
action with inhibitory receptors. For reasons that are
poorly understood, HLA-C is normally expressed on the
cell surface at levels approximately 10-fold less than most
HLA-A and HLA-B allotypes.9–11
Regulation of HLA-C surface expression
Maintenance of a low HLA-C surface expression pheno-
type is achieved at the transcriptional, translational and
post-translational levels (Fig. 1). It has been known since
1995 that HLA-C heavy chain mRNA turns over at a
rapid rate.10 However, a new study has found an explana-
tion for this observation. MicroRNA (miRNA) target
sequences have now been identified in the 30 untranslated
region (UTR) of the HLA-C gene.12 One target site in
particular was found to have functional significance for
HLA-C surface expression; a single base pair insertion or
deletion at position 263 downstream of the HLA-C stop
codon affects the binding of miRNA-148a and corre-
spondingly affects HLA-C surface expression (Fig. 1).12
In addition, HLA-C heavy chain proteins do not effi-
ciently associate with b2M.
10,13–15 The HLA-C molecules
present a more restricted repertoire of peptides than
HLA-A or -B, which leads to accumulation of HLA-C
heavy chains in the endoplasmic reticulum and ultimately
to degradation of the retained immature HLA-C mole-
cules waiting for peptide loading (Fig. 1).11,13,16
Recent studies have demonstrated that a di-hydropho-
bic signal in the HLA-C cytoplasmic tail (Fig. 2) also lim-
its cell surface expression by promoting internalization
and degradation of HLA-C16 (Fig. 1). Interestingly, Schae-
fer et al.16 found that antigen-presenting cells (APCs)
express higher levels of HLA-C on the cell surface than
other cell types. The up-regulation of HLA-C occurs upon
macrophage differentiation and is regulated by phosphor-
ylation of a serine residue adjacent to the di-hydrophobic
signal (S335)
16 (Fig. 2). The tightly regulated cell surface
expression of HLA-C is one indication that HLA-C plays
an important role in an effective immune response.
High HLA-C expression on APCs suggests that HLA-C
may serve a specific role in MHC-I pathways unique to
these cell types. For example, APCs can cross-present
exogenous antigens in association with co-stimulatory
molecules, a process essential for the efficient priming of
naive CD8+ T cells. However, uninfected APCs cross-pre-
senting foreign antigens in association with MHC-I could
also be a target of CTLs once they have developed effector
functions. Lysis of cross-presenting APCs would limit the
duration of effective naive T-cell priming. Because HLA-
C binds to inhibitory KIR that are up-regulated upon
acquisition of CTL effector functions,17 it is possible that
HLA-C plays a role in limiting CTL lysis of cross-present-
ing APCs. Prolonged survival of cross-presenting APCs
could facilitate persistent priming of naive CD8+ T cells,
which might be beneficial in chronic infection with evolv-
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Figure 1. HLA-C surface expression is regulated through multiple
mechanisms. (a) The presence of a single base pair insertion poly-
morphism in the 30-untranslated region (263ins) of HLA-C mRNA
(wavy line) results in the creation of a microRNA binding site caus-
ing post-transcriptional cleavage or destabilization. (b) Once trans-
lated, the HLA-C heavy chain does not efficiently associate with b2-
microglobulin (b2M; blue circle) in the endoplasmic reticulum (ER).
(c) HLA-C is able to bind a limited repertoire of peptides, and mole-
cules accumulating in the ER waiting for peptide loading are eventu-
ally targeted for degradation. (d) Once on the plasma membrane
(PM), the rate of HLA-C internalization and lysosomal degradation
is regulated by phosphorylation of serine residue 335.
Figure 2. HLA-A, HLA-B and HLA-C cytoplasmic tail sequences.
Y320, A324 and D327 are required for Nef-mediated AP-1 recruitment
and MHC-I down-modulation of HLA-A and HLA-B cytoplasmic
tails. Y320 and D327 are absent in HLA-C cytoplasmic tail sequences,
which are not down-modulated by Nef. HLA-C is internalized more
rapidly than HLA-A and HLA-B because of a di-hydrophobic motif
(L336I337) present in the cytoplasmic tail that is regulated by phos-
phorylation of an adjacent residue (S335).
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HLA-C and NK cell recognition
As mentioned above, almost all HLA-C allotypes are rec-
ognized by KIRs on NK cells and mature effector CTLs.
On NK cells, inhibitory KIRs monitor for ‘missing self’
resulting from MHC class I down-modulation on virally
infected or malignant cells which otherwise would escape
CTL recognition and lysis.18,19 HLA-C allotypes dominate
over HLA-A and HLA-B allotypes as a source of ligands
for KIRs6 and inhibitory receptors for HLA-C ligands are
dominant until activating signals overcome inhibi-
tion.16,20,21 Activating KIRs are thought to have a weaker
binding affinity for the same ligand and are probably
involved in recognizing ‘changed self’, such as presenta-
tion of stress peptides associated with infection or malig-
nancy by MHC class I molecules.18 Inhibitory receptors
are characterized by a long cytoplasmic tail with an
immunoreceptor tyrosine inhibitory motif whereas acti-
vating KIR have a short tail lacking the tyrosine residue.21
The KIR locus, which is located in the leucocyte recep-
tor complex, is highly polymorphic and is comprised of a
family of 14 genes, eight inhibitory, six activating and
two pseudo genes.22–24 Most of the ligands for KIRs are
still undefined but the dominant ligands that have been
identified so far are the C1 and C2 epitopes of
HLA-C.25–28 C1 allotypes (HLA-Cw1, -Cw3, -Cw7, -Cw8,
-Cw13 and -Cw14) are defined as having an asparagine at
residue 80 and are the ligands for the inhibitory receptors
KIR2DL2 and KIR2DL3.20,28,29 C2 allotypes (HLA-Cw2, -
Cw4, -Cw5, -Cw6, -Cw17 and -Cw18) have a lysine at
this residue and can act as ligand for inhibitory receptor
KIR2DL1 and for activating receptor KIR2DS1.20
The MHC and KIR loci are physically unlinked and
located on separate chromosomes in the human genome.
Both loci are highly polymorphic, and for any functional
KIR-HLA allelic pairing, it is possible that both, only one,
or neither are present in an individual.19,20 The presence
of only one allele of the KIR-HLA pair would be func-
tionally null.19 In addition, the frequency and intensity
with which a particular KIR allele is expressed is deter-
mined during maturation and is subsequently fixed.19 The
interactions between the inhibitory receptors KIR2DL1,
KIR2DL2/3 and KIR3DL1 and their HLA-C inhibitory
ligands have an active role in NK cell education during
their maturation.6 These interactions are highly variable
and result in a diverse response to infection and malig-
nancy. This may be because HLA-C is the most recently
evolved of the MHC class I genes and is subject to evolu-
tion and pathogen-mediated selection.6,20
The HLA-C allele and HIV disease
To help evade the anti-HIV CTL response, HIV encodes
the accessory protein Nef, which disrupts antigen presen-
tation in association with MHC-I by re-directing HLA-A
and HLA-B molecules from the cell surface to lysosomal
compartments for degradation. The HIV Nef protein lim-
its CTL recognition by reducing the MHC class I mole-
cules presenting HIV-derived peptides on the cell
surface.30 Down-modulation by Nef is efficient but not
complete, as evidenced by the presence of anti-HIV CTLs
and the emergence of HIV escape mutants capable of
generating higher viral loads after evolving resistance to
CTLs.31
To disrupt the cell surface expression of HLA-A and
HLA-B molecules, Nef binds to the cytoplasmic tail
domain and promotes the association of the conserved
MHC-I cytoplasmic tail tyrosine residue with the clathrin
adaptor protein 1 (AP-1)32,33 The AP-1 complex contains
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Figure 3. High HLA-C expression may enhance cytotoxic T lympho-
cyte (CTL) priming. During cross-presentation of foreign peptides
by antigen-presenting cells (APCs), high expression of HLA-C mole-
cules may allow more effective stimulation of the CD8+ T-cell
response through several mechanisms. Left panel: MHC class I mole-
cules cross present foreign peptides to naive CD8+ T cells to induce
maturation into epitope-specific effector CTLs. Because of its func-
tion as an inhibitory killer cell immunoglobulin-like receptor (KIR)
ligand, high HLA-C surface expression may inhibit lysis of unin-
fected, cross-presenting cells by fully mature effector CTLs that up-
regulate KIRs. This would promote persistent priming of naive
T cells in chronic infection. Right panel: Lower HLA-C surface
expression may result in the loss of KIR inhibitory ligand protection
for the uninfected APCs and in loss of cross-presenting cells once
mature effector CTLs have developed. Loss of cross-presenting APCs
following CTL maturation may be beneficial to turn off cross-presen-
tation and down-regulate the immune response but may be detri-
mental in chronic infection of a host by a virus that can vary its
epitopes.
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a tyrosine binding pocket in the mu subunit that is
required for this interaction. Significantly, HLA-C cyto-
plasmic tails lack two amino acids necessary for this inter-
action (Fig. 2). As a result, the HIV-1 Nef protein does
not down-modulate HLA-C molecules from the cell sur-
face34 and so HLA-C may have a unique role in present-
ing antigens to CTLs in HIV disease (Fig. 4).
HLA-C and host genetic factors that influence
HIV disease progression
During primary HIV infection, the host immune response
plays a critical role in controlling HIV replication and
these responses typically result in a significant decrease in
plasma viral load.18,35 At 18–24 months after seroconver-
sion the amount of virus present has reached an equilib-
rium, termed the viral load set point.36–38 Although there
is great variability in the viral set point between infected
individuals, many patients have stable levels exceeding
10 000 RNA copies/ml of blood.1 In a typical course of
infection, most individuals will progress to AIDS 7–
11 years after infection without antiviral therapy; how-
ever, a subset of patients will have a more rapid
(< 2 years) disease course or alternatively virtually no dis-
ease progression at all.39–42
To identify host genetic factors that influence HIV dis-
ease progression, a number of investigators have per-
formed genome-wide studies to identify single nucleotide
polymorphisms (SNPs) that correlate with disease out-
come. One SNP upstream of HLA-C (-35C/T) has been
shown to be a major determinant accounting for the viral
load set point.1–3 The -35C allele is protective, and corre-
lates with lower viral load set points and higher CD4+
T-cell counts 2 years after seroconversion.2,3,37 These data
support a role for HLA-C in early or establishing stages
of infection.37
In their second genome-wide association study, Fellay
et al.3 reported that analysis of significant SNPs in the
MHC class I locus is confounded by the pattern of long
range linkage disequilibrium in the region. The two
strongest SNPs, the HCP5 and HLA-C variants, were
found to be in partial linkage disequilibrium. They report
that in 95% of the samples with the rs2395029 minor
allele, a polymorphism within the HCP5 gene, which is
the proxy for the highly protective HLA-B*5701 allele, the
HLA-C -35C SNP is also present.3 Interestingly, they con-
clude that the effect of viral load set point and slower dis-
ease progression is a result of the presence of both alleles,
and that analyses that are not adjusted for the presence of
the HLA-C variant may in fact be over-estimating HLA-
B*5701 as the sole predictor of a protective outcome.3 It
should be noted, however, that although the -35 polymor-
phism is present in African American populations, it does
not significantly correlate with control of viral load.43,44
This suggests the possibility of another allelic combina-
tion present predominantly in the Caucasian populations
used in these analyses that may be contributing to the
observed elite controller phenotype.
Higher HLA-C surface expression is protective
Several studies have tried to determine the molecular
basis for the protective phenotype of the -35C SNP. It
was first reported that the -35C variant associates with
higher HLA-C mRNA levels in Epstein–Barr virus-trans-
formed B-cell lines.45 Further studies have now demon-
strated that high levels of HLA-C surface expression
independently correlate with a significant protection phe-
notype.44,46 Analysis of multiple -35 SNP genotypes and
HLA-C alleles demonstrate variability in surface expres-
sion of HLA-C, and those alleles that are in linkage dis-
equilibrium with -35C specifically correlate to a higher
overall surface expression, with one study reporting
































Figure 4. HLA-C surface expression and HLA-C-restricted anti-HIV
cytotoxic T lymphocytes (CTLs). Left panel: In HIV-infected individ-
uals, HLA-A and -B molecules are preferentially down-modulated by
the accessory protein Nef. Relatively high levels of HLA-C molecules
on the cell surface allow for presentation of HIV-derived peptides to
antigen-specific CTLs. The engagement of the HLA-C-specific T-cell
receptor may overcome the inhibitory signal of HLA-C interaction
with killer cell immunoglobulin-like receptors (KIRs) on mature
effector CTLs, allowing for efficient recognition and lysis of the
infected cell. However, the remaining HLA-C also results in a potent
inhibition of natural killer cell-mediated recognition and lysis. Right
panel: Lower HLA-C surface expression coupled with HLA-A and -B
down-modulation in the context of HIV infection may result in a
decrease in efficient CTL recognition and lysis of the infected cell.
The lower steady-state surface expression of HLA-C may still allow
for inhibition of NK cells expressing KIRs.
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approximately 17-fold higher on average for -35CC sub-
jects compared with -35TT subjects.44,46 The -35T SNP
does not correlate perfectly with low HLA-C expression
levels, however, as there is overlap in the distribution of
HLA-C surface expression between CC, CT and TT geno-
types.46,47 There are individuals with a -35TT genotype
that exhibit low viral-load set points that also express
HLA-C mRNA levels as high as those with the -35CC
genotype.47 These data suggest that the HLA-C allele and
its specific level of surface expression is the controlling
factor in viral load.
One of the most significant alleles identified with
higher viral loads and more rapid disease progression is
HLA-Cw7, which is in strong linkage disequilibrium with
-35T.1 HLA-Cw7 is a common haplotype, and has been
shown to have very low surface expression.44 The HLA-C
surface expression in -35TT individuals who were homo-
zygous for HLA-Cw7 was five-fold lower than -35CC
individuals who were HLA-Cw7 null.44 In fact, results
from Corrah et al.44 suggest that the most significant con-
tribution to the -35 SNP association with HIV disease
progression comes from the HLA-Cw7 allele. HLA-Cw7
has been shown previously to associate with more rapid
disease progression;1 however, exclusion of individuals
who were homozygous for HLA-Cw7 did not lose signifi-
cance for the association of the -35CC genotype with con-
trol of HIV infection.44 These data suggest that although
low HLA-C surface expression from HLA-Cw7 is signifi-
cant for rapid disease progression, the protective effect of
the -35CC genotype deserves further characterization.
Significantly, the recent study by Kulkarni et al.12 found
the polymorphic miRNA-148a binding site in the HLA-C
30UTR to be in strong linkage disequilibrium with the -35
SNP. Their analysis found an association between the elite
control of HIV infection and a deletion at position 263 in
the HLA-C 30 UTR, which disrupts the miRNA-148a
binding site. Correspondingly, there was an association
between poor control of HIV infection and an insertion
polymorphism that created an miRNA-148a recognition
sequence.12 The linkage disequilibrium of the -35SNP
with the 30UTR miRNA-148a binding site polymorphisms
offers a functional explanation for the observed differ-
ences in HLA-C surface expression among individuals
and the associated control of HIV disease.
HLA-C and CTLs in HIV disease
One of the possible explanations for the observed protec-
tive effect of higher HLA-C surface expression is improved
presentation of antigens by HLA-C to CTLs. Several lines
of evidence support the significance of CTLs in the control
of HIV infection. The appearance of HIV-specific CD8+ T
cells following acute infection correlates with a reduction
in viral replication and the establishment of a viral-load
set point.48 There is also evidence for the outgrowth of
escape mutants within HIV epitopes targeted by CTLs,
which demonstrates that CTLs exert pressure on the
virus.49–56 Furthermore, a subset of MHC class I alleles
confer protection from progression to AIDS.50,57,58
Recent evidence indicates that the HLA-C mediated
CTL response to HIV infection may be important.
Adnan et al.59 demonstrated inhibition of HIV replication
in vitro using HLA-C*03, -07, -15 -restricted HIV-1-spe-
cific CTL clones. By examining HLA-driven virus evolu-
tion in an African cohort infected with HIV-1 clade C,
Rousseau et al.60 also showed that HLA-C*04-restricted
CTLs behave in a functionally similar manner to HLA-B-
restricted CTLs and contribute to the in vivo CTL
response, although HLA-B-restricted CTLs were found to
be stronger overall. Finally, Makadzange et al.61
characterized HLA-C-restricted CTLs in an HIV-infected
cohort and found that these CTLs contributed up to 54%
of the total CTL response. In vitro analyses of these HLA-
C-restricted CTLs demonstrated surface markers and
activities to be phenotypically identical to HLA-A- or
HLA-B-derived CTLs.61
The HIV variants that alter CTL epitopes allow the
virally infected cell to evade CTL recognition and their
existence provides evidence that CTLs exert anti-viral
pressure in vivo. These substitutions sometimes result in a
fitness cost for the virus that leads to lower viral
loads.62,63 Recently, two studies reported HIV escape
mutants within CTL epitopes restricted to two different
HLA-C alleles (HLA-Cw*-03 and HLA-Cw*1202).64,65 In
the study by Honeyborne et al.64 fitness constraints result-
ing from escape mutations were compensated for by
mutations elsewhere within the Gag protein. The study by
Honda et al.65 described CTLs directed against HLA-
Cw*1202-restricted Pol epitopes that effectively sup-
pressed HIV replication in vitro and that resulted in
escape mutations in vivo. Interestingly, the HLA-Cw*1202
allele used in their analysis is in linkage disequilibrium
with the -35CC allele.46 These data suggest that HLA-C-
restricted CTLs may contribute to the control of viral
replication in vivo.
Evolution of HIV Nef in response to HLA-C allele
variation
Although the -35C allele is significantly associated with
lower HIV viral load set point and slower disease progres-
sion than the -35T allele, the distributions overlap. This
would suggest that some of the alleles associated with the
-35C SNP may not induce an effective CTL response.
Alternatively, the virus may compensate by evolving new
mechanisms to evade the immune system. To examine
this, Specht et al. identified subjects with the protective -
35CC genotype but that exhibited high viral loads. They
isolated HIV nef alleles and asked whether Nef had
acquired the ability to down-modulate HLA-C in these
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patients.47 Interestingly, none of the Nef variants that they
isolated affected HLA-C expression levels. These data sug-
gest that there may be a substantial fitness cost to the
virus if HLA-C levels are further reduced, which may be
explained by the role of HLA-C as a ligand for inhibitory
KIRs on NK cells (Fig. 4).
Surprisingly, Nef proteins isolated from patients with
both the -35CC genotype and high viral loads had
evolved to more effectively perform other Nef functions
beneficial to the virus. For example, they were more effi-
cient at down-modulating the HIV co-receptors CD4
and CXCR4, the T-cell co-stimulatory molecule CD28,
and MHC class II invariant chain Ii than Nef proteins
isolated from people with the -35TT genotype.47 Hence,
in some people, the benefit of higher HLA-C levels may
be overcome by the evolution of a generally more patho-
genic virus.
Conclusion
Infection with HIV has a variable disease course and the
host factors that influence rapid versus slow disease
progression are not well understood. Individuals with
high HLA-C expression may benefit from more effective
recognition and lysis of HIV-infected cells by HLA-C-
restricted CTLs (Fig. 4). Additionally, higher HLA-C
expression in cross-presenting APCs may allow continued
naive CD8+ T-cell priming during the chronic phase of
infection, which would allow the development of new
CTL responses to variant epitopes restricted to a variety
of MHC-I allotypes (Fig. 3). The benefit of high HLA-C
expression may be limited by the inhibitory effect of
HLA-C on the NK cell (and possibly CTL) response. Ele-
vated HLA-C expression may increase the risk of some
types of infections or malignancies that require an effec-
tive NK cell response for control.66 The relative expres-
sion level of HLA-C, which has both costs and benefits, is
an important phenotype that may evolve in response to
pressure from pathogens.
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